Ethan Wajswol1, Tarek Jazmati2, Sohail Contractor2, Abhishek Kumar3. 1. Rutgers New Jersey Medical School, Newark, NJ, USA. 2. Department of Radiology, New Jersey Medical School, Rutgers University, 150 Bergen Street, UH Suite C-318 A, Newark, NJ, 07103, USA. 3. Department of Radiology, New Jersey Medical School, Rutgers University, 150 Bergen Street, UH Suite C-318 A, Newark, NJ, 07103, USA. kumarab@umdnj.edu.
Abstract
PURPOSE: To evaluate the safety and effectiveness of n-butyl cyanoacrylate (NBCA) for portal vein embolization (PVE) when used to induce contralateral future liver remnant (FLR) hypertrophy in patients undergoing planned hepatic resection for hepatic malignancy. MATERIALS AND METHODS: The PubMed database (including articles indexed by MEDLINE) was searched for articles published from 1970 to 2018 describing patients treated with PVE utilizing NBCA to induce hypertrophy of the FLR prior to contralateral hepatic lobe resection. Demographic data, embolization technique, complications of embolization, resultant FLR hypertrophy, and surgical outcomes were obtained when available. A meta-analysis was performed to determine the cumulative relative hypertrophy rate of the FLR following PVE with NBCA. RESULTS: The literature search yielded 18 relevant articles. Six hundred and seven patients (383 men, 220 women; mean age 60.7 years) with procedures describing PVE utilizing NBCA were reviewed. The most common underlying hepatic malignancies were colorectal metastases (n = 348), followed by cholangiocarcinomas (n = 92), and hepatocellular carcinomas (n = 89). Technical success was reportedly achieved in 603/607 patients, for a success rate of 99.3%. Fixed effects meta-analysis of the relative hypertrophy rate of the FLR among studies resulted in an aggregate rate of 49.4 ± 1.3%. Of the patients who underwent attempted PVE, 461/607 (75.9%) eventually underwent surgical resection. Major complications following PVE occurred in 19 patients (3.13%), while minor complications following PVE occurred in 38 patients (6.26%). CONCLUSIONS: PVE utilizing NBCA to induce hypertrophy of the FLR prior to contralateral lobe resection in the setting of hepatic malignancy is safe and effective. LEVEL OF EVIDENCE: Level IIa-Systematic review of cohort studies.
PURPOSE: To evaluate the safety and effectiveness of n-butyl cyanoacrylate (NBCA) for portal vein embolization (PVE) when used to induce contralateral future liver remnant (FLR) hypertrophy in patients undergoing planned hepatic resection for hepatic malignancy. MATERIALS AND METHODS: The PubMed database (including articles indexed by MEDLINE) was searched for articles published from 1970 to 2018 describing patients treated with PVE utilizing NBCA to induce hypertrophy of the FLR prior to contralateral hepatic lobe resection. Demographic data, embolization technique, complications of embolization, resultant FLR hypertrophy, and surgical outcomes were obtained when available. A meta-analysis was performed to determine the cumulative relative hypertrophy rate of the FLR following PVE with NBCA. RESULTS: The literature search yielded 18 relevant articles. Six hundred and seven patients (383 men, 220 women; mean age 60.7 years) with procedures describing PVE utilizing NBCA were reviewed. The most common underlying hepatic malignancies were colorectal metastases (n = 348), followed by cholangiocarcinomas (n = 92), and hepatocellular carcinomas (n = 89). Technical success was reportedly achieved in 603/607 patients, for a success rate of 99.3%. Fixed effects meta-analysis of the relative hypertrophy rate of the FLR among studies resulted in an aggregate rate of 49.4 ± 1.3%. Of the patients who underwent attempted PVE, 461/607 (75.9%) eventually underwent surgical resection. Major complications following PVE occurred in 19 patients (3.13%), while minor complications following PVE occurred in 38 patients (6.26%). CONCLUSIONS: PVE utilizing NBCA to induce hypertrophy of the FLR prior to contralateral lobe resection in the setting of hepatic malignancy is safe and effective. LEVEL OF EVIDENCE: Level IIa-Systematic review of cohort studies.
Authors: Roland Brüning; Martin Schneider; Michel Tiede; Peter Wohlmuth; Gregor Stavrou; Thomas von Hahn; Andrea Ehrenfeld; Tim Reese; Georgios Makridis; Axel Stang; Karl J Oldhafer Journal: CVIR Endovasc Date: 2021-05-17
Authors: Sébastien Gautier; Olivier Chevallier; Charles Mastier; Philippe d'Athis; Nicolas Falvo; Frank Pilleul; Marco Midulla; Patrick Rat; Olivier Facy; Romaric Loffroy Journal: Quant Imaging Med Surg Date: 2021-02
Authors: Celeste Del Basso; Martin Gaillard; Panagiotis Lainas; Stella Zervaki; Gabriel Perlemuter; Pierre Chagué; Laurence Rocher; Cosmin Sebastian Voican; Ibrahim Dagher; Hadrien Tranchart Journal: World J Hepatol Date: 2021-11-27
Authors: Philip C Müller; Michael Linecker; Elvan O Kirimker; Christian E Oberkofler; Pierre-Alain Clavien; Deniz Balci; Henrik Petrowsky Journal: Langenbecks Arch Surg Date: 2021-03-19 Impact factor: 3.445